HomeGeneticsConditionCone-rod dystrophy
Back to Condition
Cone-rod dystrophy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Cone-rod dystrophy

Cone-rod dystrophy is a group of inherited eye disorders that cause progressive vision loss due to the deterioration of light-sensing cells in the retina.

Overview

Cone-rod dystrophy affects the retina, the light-sensitive tissue at the back of the eye. The condition is characterized by the gradual breakdown of photoreceptor cells. There are more than 30 types of the disorder, which can occur alone or as part of a larger syndrome.

Symptoms

Symptoms often begin in childhood and progress over time:

  • Early signs: Decreased sharpness of vision (visual acuity) and increased sensitivity to light (photophobia).
  • Progression: Impaired color vision (dyschromatopsia), blind spots (scotomas) in the center of the visual field, and partial side (peripheral) vision loss.
  • Advanced stages: Night blindness, worsening peripheral vision, and involuntary eye movements (nystagmus). Most affected individuals are legally blind by mid-adulthood.

Causes

The retina contains two types of photoreceptors: rods (for low-light vision) and cones (for bright light and color vision). Mutations in more than 30 genes—such as ABCA4, GUCY2D, and CRX—disrupt the structure and function of these cells. In cone-rod dystrophy, cones typically deteriorate before rods, explaining why light sensitivity and color vision impairment are often the first symptoms.

Inheritance

The condition can be inherited in several patterns:

  • Autosomal recessive: Both copies of the gene in each cell have mutations. Parents are typically carriers without symptoms.
  • Autosomal dominant: One copy of the altered gene is sufficient to cause the disorder.
  • X-linked: Rare forms where the gene is located on the X chromosome. Males are affected more frequently than females.

Frequently Asked Questions

Yes. Early genetic testing can confirm the specific subtype, guide prognosis, and determine eligibility for any gene‑specific clinical trials. Most ophthalmology centers can order a targeted retinal dystrophy panel after a thorough eye exam and family history review.
Magnifying handheld or stand‑alone readers, high‑contrast large‑print books, and electronic devices with adjustable font size and background color are first‑line. For mobility, a wide‑field retinal prosthesis (e.g., Argus II) is not approved for cone‑rod dystrophy, but tinted lenses that reduce glare and a white cane or guide dog can improve safety.
Currently, no FDA‑approved cure exists, but several avenues are in trial: (1) gene‑replacement therapy for GUCY2D‑related cases, (2) oral retinoid analogs (e.g., 9‑cis‑retinyl acetate) aimed at supporting photoreceptor metabolism, and (3) neuroprotective agents such as ciliary neurotrophic factor (CNTF) implants. Ask your retina specialist about enrollment criteria and travel requirements.
Night blindness itself is not an emergency, but it can increase crash risk. If you cannot see road signs, pedestrians, or hazards within a safe distance, stop driving after dusk and consider a professional driving assessment. Use peripheral lighting, avoid high‑glare headlights, and keep a well‑lit vehicle interior. If you experience sudden worsening of night vision, report it promptly as it may signal rapid rod degeneration.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab